AstraZeneca reports that positive results from a phase III trial showed that Tagrisso (osimertinib) 'significantly' improved progression-free survival (PFS) in patients with unresectable EGFR-mutated stage III non-small cell lung cancer after chemoradiotherapy (CRT), compared with placebo after CRT.

Tagrisso reduced the risk of disease progression or death by 84%, with a median PFS of 39.1 months versus 5.6 months for placebo.

Tagrisso extended progression-free survival by more than three years in this potentially curative setting, reinforcing the need to test and diagnose patients early", commented Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca.


Copyright (c) 2024 CercleFinance.com. All rights reserved.